<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">CTJ</journal-id>
<journal-id journal-id-type="hwp">spctj</journal-id>
<journal-id journal-id-type="nlm-ta">Clin Trials</journal-id>
<journal-title>Clinical Trials</journal-title>
<issn pub-type="ppub">1740-7745</issn>
<issn pub-type="epub">1740-7753</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1740774512470317</article-id>
<article-id pub-id-type="publisher-id">10.1177_1740774512470317</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Evaluating the impact of imputations for missing participant outcome data in a network meta-analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Spineli</surname><given-names>Loukia M</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512470317">a</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Higgins</surname><given-names>Julian PT</given-names></name>
<xref ref-type="aff" rid="aff2-1740774512470317">b</xref>
<xref ref-type="aff" rid="aff3-1740774512470317">c</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Cipriani</surname><given-names>Andrea</given-names></name>
<xref ref-type="aff" rid="aff4-1740774512470317">d</xref>
<xref ref-type="aff" rid="aff5-1740774512470317">e</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Leucht</surname><given-names>Stefan</given-names></name>
<xref ref-type="aff" rid="aff6-1740774512470317">f</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Salanti</surname><given-names>Georgia</given-names></name>
<xref ref-type="aff" rid="aff1-1740774512470317">a</xref>
</contrib>
</contrib-group>
<aff id="aff1-1740774512470317"><label>a</label>Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, University Campus, Ioannina, Greece</aff>
<aff id="aff2-1740774512470317"><label>b</label>MRC Biostatistics Unit, Cambridge, UK</aff>
<aff id="aff3-1740774512470317"><label>c</label>Centre for Reviews and Dissemination, University of York, York, UK</aff>
<aff id="aff4-1740774512470317"><label>d</label>Department of Public Health and Community Medicine, Section of Psychiatry, University of Verona, Verona, Italy</aff>
<aff id="aff5-1740774512470317"><label>e</label>Department of Psychiatry, University of Oxford, Oxford, UK</aff>
<aff id="aff6-1740774512470317"><label>f</label>Institut für Klinische Chemie und Pathobiochemie, Klinikum rechts der Isar, Technische Universität Müchen, Munich, Germany</aff>
<author-notes>
<corresp id="corresp1-1740774512470317">Georgia Salanti, Department of Hygiene and Epidemiology, School of Medicine, University of Ioannina, University Campus, 45110 Ioannina, Greece. Email: <email>gsalanti@cc.uoi.gr</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>10</volume>
<issue>3</issue>
<fpage>378</fpage>
<lpage>388</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">The Society for Clinical Trials</copyright-holder>
</permissions>
<abstract>
<sec id="section1-1740774512470317">
<title>Background</title>
<p>In a meta-analysis of trials with missing outcome data, a parameter known as informative missing odds ratio (IMOR) can be used to quantify the relationship between informative missingness and a binary outcome. IMORs also account for the increased uncertainty due to missingness in the meta-analysis results.</p>
</sec>
<sec id="section2-1740774512470317">
<title>Purpose</title>
<p>To extend the idea of IMOR into a network meta-analysis (NMA) setting in order to explore the impact of missing outcome data on the inferences about the relative effectiveness of several competing treatments in psychiatric trials.</p>
</sec>
<sec id="section3-1740774512470317">
<title>Methods</title>
<p>IMORs were estimated in two datasets comparing anti-manic treatments and antidepressants. The outcome was response to treatments. In the original meta-analyses, missing participants were assumed to have failed regardless the treatment they were allocated to. To evaluate the robustness of this assumption in each dataset, several imputations of the missing outcomes were studied by an IMOR parameter in the NMA model. By comparing the odds ratios for efficacy under the initial analysis and under several assumptions about the missingness, we assessed the consistency of the conclusions. The missing data mechanism was studied by comparing the prior with the posterior IMOR distribution. Models were fitted using Markov chain Monte Carlo (MCMC) in WinBUGS.</p>
</sec>
<sec id="section4-1740774512470317">
<title>Results</title>
<p>In both datasets, the relative effectiveness of the treatments seems to be affected only by the two extreme imputation scenarios of worst- and best-case analyses. Moreover, heterogeneity increases in both datasets under these two extreme scenarios. Overall, there is a non-significant change on the ranking of the anti-manic and antidepressant treatments. The posterior and prior IMOR distributions are very similar showing that the data do not provide any information about the true outcome in missing participants. There is a very weak indication that missing participants tend to fail in placebo and paroxetine, while the opposite occurs for sertraline, fluoxetine, and fluvoxamine.</p>
</sec>
<sec id="section5-1740774512470317">
<title>Limitations</title>
<p>Investigation of informative missingness was limited two classes of treatments and for dichotomous outcome measures. The proportion of missing outcomes was very low overall, and hence, the power of detecting any differences in effectiveness estimated under the various imputation methods is small.</p>
</sec>
<sec id="section6-1740774512470317">
<title>Conclusions</title>
<p>Sensitivity analysis to account for missing outcome data and their uncertainty in the NMA can be undertaken by extending the idea of IMOR. In two case examples, we found no differences between the various models due to low missing data rate. In line with previous observations, data carry little information about the reason of missingness.</p>
</sec>
</abstract>
</article-meta>
</front>
<body>
<sec id="section7-1740774512470317">
<title>Background</title>
<p>Missing outcome data frequently occur in randomized controlled trials (RCTs), either because of participants leaving the study early or due to post-randomization exclusions. Missing data are a potential threat to the validity of inferences from RCTs. They lead to increased uncertainty over the effects of an intervention and, if ignored, may lead to biased estimates. It is therefore important that missing data are appropriately considered when RCTs are included in meta-analyses. Informative missing outcome data can lead to biased meta-analysis estimates as well as to high heterogeneity [<xref ref-type="bibr" rid="bibr1-1740774512470317">1</xref>,<xref ref-type="bibr" rid="bibr2-1740774512470317">2</xref>].</p>
<p>The impact of missing outcome data is frequently considered within a systematic review context using non-statistical approaches, by interpreting, for example, the summary treatment effect under the light of qualitative assessments for the risk of bias in each trial [<xref ref-type="bibr" rid="bibr3-1740774512470317">3</xref>]. Statistical methods to account for the impact of missing outcome data in the summary relative treatment effect are also available [<xref ref-type="bibr" rid="bibr4-1740774512470317">4</xref><xref ref-type="bibr" rid="bibr5-1740774512470317"/><xref ref-type="bibr" rid="bibr6-1740774512470317"/><xref ref-type="bibr" rid="bibr7-1740774512470317"/><xref ref-type="bibr" rid="bibr8-1740774512470317"/>–<xref ref-type="bibr" rid="bibr9-1740774512470317">9</xref>]. As with other applications of methods for missing data, it is important to consider different scenarios regarding the degree of ‘informativeness’:</p>
<list id="list1-1740774512470317" list-type="order">
<list-item><p><italic>Missing completely at random (MCAR)</italic>. The missing outcome is not related to any observed or unobserved variable. For instance, a missing outcome from a subject who had a car accident, or has moved house and not informed his doctor, is considered to be MCAR;</p>
</list-item>
<list-item><p><italic>Missing at random (MAR)</italic>. The status of missingness relates to observed or unobserved variables but not to the actual value of the outcome conditional on the observed variables. Consider for example an intervention aiming to reduce alcohol consumption but does not affect smoking behaviour. People who smoke tend to consume stable and high levels of alcohol. Some of these subjects may leave the trial since they cannot reduce their alcohol consumption. In a randomized trial, the proportion of smokers should be comparable between arms, resulting in similar rates of unobserved outcomes in both groups, and therefore, the relative treatment effect will be unbiased.</p>
</list-item>
<list-item><p><italic>Missing not at random or informative missing</italic>. When the missing outcome is related directly to the actual outcome value, or some unobserved variables are responsible both for the missingness and for the outcome. For instance, lack of response to an experimental treatment due to its side effects can lead to missing outcome for the corresponding subjects. In such situations, estimating relative treatment effects based on the observed data will lead to biased inferences [<xref ref-type="bibr" rid="bibr4-1740774512470317">4</xref>,<xref ref-type="bibr" rid="bibr6-1740774512470317">6</xref>].</p>
</list-item>
</list>
<p>The issue of missing outcome data is particularly pertinent to psychiatric trials [<xref ref-type="bibr" rid="bibr10-1740774512470317">10</xref>]. To minimize its impact, the ‘last observation carried forward’ (LOCF) approach is often employed. However, this has been heavily criticized and has been shown sometimes to overestimate and sometimes to underestimate treatment effects [<xref ref-type="bibr" rid="bibr11-1740774512470317">11</xref>,<xref ref-type="bibr" rid="bibr12-1740774512470317">12</xref>]. Most meta-analyses in psychiatry assume that in missing participants, the treatment has failed. Robustness of conclusions is subsequently explored in sensitivity analyses under various scenarios. However, most of these scenarios involve imputation of the outcomes in missing participants, ignoring the uncertainty in the imputations.</p>
<p>A meta-analysis model was suggested previously to better quantify uncertainty in the imputations. Key to this model is an unknown parameter that quantifies the deviance between MAR and informative missingness in each arm and trial [<xref ref-type="bibr" rid="bibr5-1740774512470317">5</xref>,<xref ref-type="bibr" rid="bibr6-1740774512470317">6</xref>]. For binary outcomes, this parameter has been called the ‘informative missing odds ratio’ (IMOR), and it describes the relationship between the unknown occurrence of the outcome among missing participants and the known outcome in observed participants. The incorporation of IMORs into the meta-analysis model allows for uncertainty in the imputations and ‘adjusts’ the overall summary effect according to the assumptions employed. Despite the elegance of this approach, it has not been applied in more than a handful of meta-analyses.</p>
<p>Network meta-analysis (NMA) is an extension to meta-analysis for the simultaneous comparison of multiple treatments [<xref ref-type="bibr" rid="bibr13-1740774512470317">13</xref>,<xref ref-type="bibr" rid="bibr14-1740774512470317">14</xref>]. Extension of the IMOR model into NMA has the potential to provide large-scale evidence about the impact of assumptions for missing outcomes into the relative effectiveness of the interventions. Moreover, as NMA typically involves more than two treatments, IMORs will offer an opportunity to explore interactions between treatments and informative missingness by employing a series models for the similarity of IMORs across arms and trials.</p>
<p>The objective of this article is to develop IMOR models for NMA and to evaluate the robustness of the findings in two recently published NMAs in the field of psychopharmacology [<xref ref-type="bibr" rid="bibr15-1740774512470317">15</xref>,<xref ref-type="bibr" rid="bibr16-1740774512470317">16</xref>]. We examine a variety of plausible scenarios regarding missing outcome data and their uncertainty. Furthermore, we aim to evaluate the degree to which data can provide evidence supporting or refuting the various scenarios regarding the occurrence of the outcome in the missing participants.</p>
</sec>
<sec id="section8-1740774512470317" sec-type="methods">
<title>Methods</title>
<sec id="section9-1740774512470317">
<title>Datasets: anti-manic and antidepressant interventions</title>
<p>We used data from two published NMAs [<xref ref-type="bibr" rid="bibr15-1740774512470317">15</xref>,<xref ref-type="bibr" rid="bibr16-1740774512470317">16</xref>]. The first dataset comprises 47 RCTs that compared 12 anti-manic treatments with another active treatment or placebo. The second dataset comprises 109 head-to-head (i.e., comparisons of two active interventions) RCTs that compared 12 second-generation antidepressants. We used placebo as the reference treatment in the former network and fluoxetine, the first marketed second-generation antidepressant, in the latter. Only studies that reported a binary efficacy outcome (i.e., number of patients with at least a 50% reduction on the severity score between baseline and endpoint on a standardized rating scale) were included in the present analysis for both datasets. Both networks are presented in Figures A1 and A2 in Appendix. In most trials in both datasets, a LOCF strategy had been implemented for patients who left the study early. However, there were further participants who did not provide any outcome data, so were not included in the LOCF analyses. It is these ‘missing participants’ that we target in our examples. The data were initially analysed using NMA models that assumed all missing values are failures.</p>
</sec>
<sec id="section10-1740774512470317">
<title>NMA model with all missing outcome data coded as failures</title>
<p>Let us denote with <italic>ns</italic> the total number of studies, where each study has <inline-formula id="inline-formula1-1740774512470317">
<mml:math display="inline" id="math1-1740774512470317">
<mml:mrow>
<mml:mi>n</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> arms, where <inline-formula id="inline-formula2-1740774512470317">
<mml:math display="inline" id="math2-1740774512470317">
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>ns</mml:mi>
</mml:mrow>
</mml:math></inline-formula>. With <inline-formula id="inline-formula3-1740774512470317">
<mml:math display="inline" id="math3-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula>, we denote the number of known failures in arm <inline-formula id="inline-formula4-1740774512470317">
<mml:math display="inline" id="math4-1740774512470317">
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:math></inline-formula> of study <inline-formula id="inline-formula5-1740774512470317">
<mml:math display="inline" id="math5-1740774512470317">
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:math></inline-formula>, with <inline-formula id="inline-formula6-1740774512470317">
<mml:math display="inline" id="math6-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> the number of known successes, with <inline-formula id="inline-formula7-1740774512470317">
<mml:math display="inline" id="math7-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>m</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> the number with missing outcome data and with <inline-formula id="inline-formula8-1740774512470317">
<mml:math display="inline" id="math8-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> the sample size. We first consider that all missing data are subjects who failed. In each treatment and each trial, the number of successes follows a binomial likelihood</p>
<p>
<disp-formula id="disp-formula1-1740774512470317">
<mml:math display="block" id="math9-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:msub>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mi>Bin</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mspace width="0.25em"/>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>ns</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mtext>and</mml:mtext>
</mml:mrow>
<mml:mspace width="0.25em"/>
<mml:mi>k</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>n</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula1-1740774512470317" xlink:href="10.1177_1740774512470317-eq1.tif"/>
</disp-formula>
</p>
<p>where <inline-formula id="inline-formula9-1740774512470317">
<mml:math display="inline" id="math10-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>m</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula></p>
<p>Now, <inline-formula id="inline-formula10-1740774512470317">
<mml:math display="inline" id="math11-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> is the probability of success in arm <italic>k</italic> of study <italic>i</italic>. The probabilities in two arms are linked through the odds ratio</p>
<p>
<disp-formula id="disp-formula2-1740774512470317">
<label>(1)</label>
<mml:math display="block" id="math12-1740774512470317">
<mml:mrow>
<mml:mi>l</mml:mi>
<mml:mi>o</mml:mi>
<mml:mi>g</mml:mi>
<mml:mi>i</mml:mi>
<mml:mi>t</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:msub>
<mml:mi>π</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>{</mml:mo> <mml:mrow>
<mml:mtable>
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:msub>
<mml:mi>u</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:mtd>
<mml:mtd>
<mml:mrow>
<mml:mi>if</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>k</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mtext>control treatment</mml:mtext>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
<mml:mtr>
<mml:mtd>
<mml:mrow>
<mml:msub>
<mml:mi>u</mml:mi>
<mml:mi>i</mml:mi>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mi>θ</mml:mi>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
<mml:mo>,</mml:mo>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:mtd>
<mml:mtd>
<mml:mrow>
<mml:mi>if</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mi>k</mml:mi>
<mml:mo>≥</mml:mo>
<mml:mn>2</mml:mn>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mtext>experimental treatment</mml:mtext>
</mml:mrow>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:mtd>
</mml:mtr>
</mml:mtable>
</mml:mrow>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-1740774512470317" xlink:href="10.1177_1740774512470317-eq2.tif"/></disp-formula>
</p>
<p>where <inline-formula id="inline-formula11-1740774512470317">
<mml:math display="inline" id="math13-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>u</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>logit</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> is the log odds of success in the control group. The parameter <inline-formula id="inline-formula12-1740774512470317">
<mml:math display="inline" id="math14-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>θ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
<mml:mo>~</mml:mo>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> is the log odds ratio (OR) of success between arm <italic>k</italic> and the control group of study <italic>i</italic>, which under the random effects assumption follows a normal distribution <inline-formula id="inline-formula13-1740774512470317">
<mml:math display="inline" id="math15-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>θ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mspace width="0.25em"/>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>τ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>, with <inline-formula id="inline-formula14-1740774512470317">
<mml:math display="inline" id="math16-1740774512470317">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>τ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math></inline-formula> the heterogeneity variance, assumed common for all comparisons. The <inline-formula id="inline-formula15-1740774512470317">
<mml:math display="inline" id="math17-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> is the mean log OR for treatment in arm <italic>k</italic> versus the treatment in the reference arm in study <italic>i</italic>. If study <italic>i</italic> compares two treatments, <italic>X</italic> to <italic>Y</italic>, then <inline-formula id="inline-formula16-1740774512470317">
<mml:math display="inline" id="math18-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>k</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>:</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>XY</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula>. For any two random treatments <italic>X</italic> and <italic>Y</italic>, the parameters <inline-formula id="inline-formula17-1740774512470317">
<mml:math display="inline" id="math19-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>XY</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> are linked through the <italic>consistency equations</italic>. Denoting with <italic>R</italic> an arbitrarily chosen overall reference treatment, it is <inline-formula id="inline-formula18-1740774512470317">
<mml:math display="inline" id="math20-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>XY</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>RY</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>RY</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> with <inline-formula id="inline-formula19-1740774512470317">
<mml:math display="inline" id="math21-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>XX</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math></inline-formula> [<xref ref-type="bibr" rid="bibr14-1740774512470317">14</xref>,<xref ref-type="bibr" rid="bibr17-1740774512470317">17</xref>].</p>
<p>Ranking probabilities for all treatments can be obtained, and cumulative ranking curves can be summarized using surface under the cumulative ranking (SUCRA) [<xref ref-type="bibr" rid="bibr13-1740774512470317">13</xref>].</p>
</sec>
<sec id="section11-1740774512470317">
<title>Extending the NMA to include IMOR parameters</title>
<p>To take into consideration the missing data, the data from study are <inline-formula id="inline-formula20-1740774512470317">
<mml:math display="inline" id="math22-1740774512470317">
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:math></inline-formula> written as the vector <inline-formula id="inline-formula21-1740774512470317">
<mml:math display="inline" id="math23-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>y</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>m</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>, which follows a multinomial likelihood</p>
<p>
<disp-formula id="disp-formula3-1740774512470317">
<mml:math display="block" id="math24-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>y</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>r</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>f</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>m</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>~</mml:mo>
<mml:mi>Multi</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>n</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>,</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mspace width="0.25em"/>
<mml:mi>i</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>ns</mml:mi>
<mml:mspace width="0.25em"/>
<mml:mrow>
<mml:mtext>and</mml:mtext>
</mml:mrow>
<mml:mspace width="0.25em"/>
<mml:mi>k</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mo>…</mml:mo>
<mml:mo>,</mml:mo>
<mml:mi>n</mml:mi>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula3-1740774512470317" xlink:href="10.1177_1740774512470317-eq3.tif"/>
</disp-formula>
</p>
<p>where</p>
<p>
<disp-formula id="disp-formula4-1740774512470317">
<mml:math display="block" id="math25-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula4-1740774512470317" xlink:href="10.1177_1740774512470317-eq4.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula5-1740774512470317">
<mml:math display="block" id="math26-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula5-1740774512470317" xlink:href="10.1177_1740774512470317-eq5.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula6-1740774512470317">
<mml:math display="block" id="math27-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>p</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>3</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>+</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula6-1740774512470317" xlink:href="10.1177_1740774512470317-eq6.tif"/>
</disp-formula>
</p>
<p>are the probabilities for observed success, observed failure, and missing data (in failure or success), respectively. The parameter <inline-formula id="inline-formula22-1740774512470317">
<mml:math display="inline" id="math28-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> denotes the overall probability of success (across observed and missing participants), and <inline-formula id="inline-formula23-1740774512470317">
<mml:math display="inline" id="math29-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> and <inline-formula id="inline-formula24-1740774512470317">
<mml:math display="inline" id="math30-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> denote the probability that a failure is missing and the probability of a success is missing, respectively [<xref ref-type="bibr" rid="bibr5-1740774512470317">5</xref>]. Then, the parameterization of the probabilities <inline-formula id="inline-formula25-1740774512470317">
<mml:math display="inline" id="math31-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>π</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> to obtain log ORs is as in equation (1), and the rest of the model is as described in the paragraph that follows the equation.</p>
<p>The probabilities of missing failure and success <inline-formula id="inline-formula26-1740774512470317">
<mml:math display="inline" id="math32-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> and <inline-formula id="inline-formula27-1740774512470317">
<mml:math display="inline" id="math33-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> are related through the IMOR. Specifically, since the IMOR is the odds that a success is missing over the odds that a failure is missing, we can write the log IMOR as <inline-formula id="inline-formula28-1740774512470317">
<mml:math display="inline" id="math34-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mi>logit</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>−</mml:mo>
<mml:mi>logit</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>. The probabilities <inline-formula id="inline-formula29-1740774512470317">
<mml:math display="inline" id="math35-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> and <inline-formula id="inline-formula30-1740774512470317">
<mml:math display="inline" id="math36-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> can then be parameterized with respect to <inline-formula id="inline-formula31-1740774512470317">
<mml:math display="inline" id="math37-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> and a parameter <inline-formula id="inline-formula32-1740774512470317">
<mml:math display="inline" id="math38-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mo stretchy="false">[</mml:mo>
<mml:mi>logit</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>+</mml:mo>
<mml:mi>logit</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">]</mml:mo>
<mml:mo stretchy="false">/</mml:mo>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:math></inline-formula> that represents the average missingness across failures and successes</p>
<p>
<disp-formula id="disp-formula7-1740774512470317">
<mml:math display="block" id="math39-1740774512470317">
<mml:mrow>
<mml:mi>logit</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>−</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>5</mml:mn>
<mml:mspace width="0.25em"/>
<mml:mo>×</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula7-1740774512470317" xlink:href="10.1177_1740774512470317-eq7.tif"/>
</disp-formula>
</p>
<p>
<disp-formula id="disp-formula8-1740774512470317">
<mml:math display="block" id="math40-1740774512470317">
<mml:mrow>
<mml:mi>logit</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>a</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>1</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>)</mml:mo>
</mml:mrow>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>+</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>5</mml:mn>
<mml:mspace width="0.25em"/>
<mml:mo>×</mml:mo>
<mml:mspace width="0.25em"/>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula8-1740774512470317" xlink:href="10.1177_1740774512470317-eq8.tif"/>
</disp-formula>
</p>
<p>We can explore different models that correspond to various missing mechanisms across trials and treatments by modelling the parameters <inline-formula id="inline-formula33-1740774512470317">
<mml:math display="inline" id="math41-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula>. Setting <inline-formula id="inline-formula34-1740774512470317">
<mml:math display="inline" id="math42-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> to zero is equivalent to the MAR assumption; the odds of missingness between successes and failures are equal. Negative <inline-formula id="inline-formula35-1740774512470317">
<mml:math display="inline" id="math43-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> values suggest that the odds of missing given the success are less than the odds for the failures. Deviations from MAR can be modelled by setting <inline-formula id="inline-formula36-1740774512470317">
<mml:math display="inline" id="math44-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>≠</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math></inline-formula> or by introducing some uncertainty in their common distribution. Very large positive and negative <inline-formula id="inline-formula37-1740774512470317">
<mml:math display="inline" id="math45-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> values can be used to reflect the assumptions that all missing values are successes and failures, respectively.</p>
</sec>
<sec id="section12-1740774512470317">
<title>Assumptions about IMORs</title>
<p>The IMOR parameters can take specific fixed values, or assumptions about their similarity across trials and treatments can be employed. We distinguish between two approaches. The first approach treats <inline-formula id="inline-formula38-1740774512470317">
<mml:math display="inline" id="math46-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> as fixed values and mimics the ‘naïve’ data imputation process. The second approach makes assumptions about the similarities of the parameters <inline-formula id="inline-formula39-1740774512470317">
<mml:math display="inline" id="math47-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> across studies and treatments and employs distributions to reflect uncertainty about the imputation process.</p>
</sec>
<sec id="section13-1740774512470317">
<title>Fixed IMOR models</title>
<p>Several variants of a fixed IMOR model can be employed under different assumptions about the missing outcomes:</p>
<list id="list2-1740774512470317" list-type="order">
<list-item>
<p>In MAR model, we assume that <inline-formula id="inline-formula40-1740774512470317">
<mml:math display="inline" id="math48-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math></inline-formula>; the odds of unobserved success are the same to the odds of unobserved failure in any arm and study;</p>
</list-item>
<list-item>
<p>In an all missing failures (AMF) model, we assume that <inline-formula id="inline-formula41-1740774512470317">
<mml:math display="inline" id="math49-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mo>−</mml:mo>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:math></inline-formula>;</p>
</list-item>
<list-item>
<p>In an all missing successes (AMS) model, we assume that <inline-formula id="inline-formula42-1740774512470317">
<mml:math display="inline" id="math50-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:math></inline-formula>;</p>
</list-item>
<list-item>
<p>In a best-case (BC) model, we assume that <inline-formula id="inline-formula43-1740774512470317">
<mml:math display="inline" id="math51-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mo>−</mml:mo>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:math></inline-formula> for the placebo arm and <inline-formula id="inline-formula44-1740774512470317">
<mml:math display="inline" id="math52-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:math></inline-formula> for the active treatments;</p>
</list-item>
<list-item>
<p>In a worst-case (WC) model, we assume that <inline-formula id="inline-formula45-1740774512470317">
<mml:math display="inline" id="math53-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:math></inline-formula> for the placebo arm and <inline-formula id="inline-formula46-1740774512470317">
<mml:math display="inline" id="math54-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mo>−</mml:mo>
<mml:mn>50</mml:mn>
</mml:mrow>
</mml:math></inline-formula> for the active treatments.</p>
</list-item>
</list>
<p>The models above are equivalent to imputing the missing values <inline-formula id="inline-formula47-1740774512470317">
<mml:math display="inline" id="math55-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>m</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> as failures or successes (specific to each scenario) before analysing the data.</p>
</sec>
<sec id="section14-1740774512470317">
<title>Common and treatment-specific IMOR models</title>
<p>When <inline-formula id="inline-formula48-1740774512470317">
<mml:math display="inline" id="math56-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> are fixed to a specific value, missing values are imputed without uncertainty. An alternative would be to employ a prior distribution reflecting the uncertainty in the imputations. For example, instead of setting <inline-formula id="inline-formula49-1740774512470317">
<mml:math display="inline" id="math57-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math></inline-formula>, we might believe that MAR holds ‘on average’ and fit a distribution <inline-formula id="inline-formula50-1740774512470317">
<mml:math display="inline" id="math58-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
</mml:msub>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> with <inline-formula id="inline-formula51-1740774512470317">
<mml:math display="inline" id="math59-1740774512470317">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math></inline-formula> allowing for small random departures from MAR. To restrict the number of parameters, we can assume log IMORs to be equal across arms and/or studies. Several possibilities exist; for a detailed description, see White <italic>et al</italic>. [<xref ref-type="bibr" rid="bibr5-1740774512470317">5</xref>]. Here we will employ the common IMOR (On Average MAR) model and variations of a treatment-specific IMOR model.</p>
<p>In the common IMOR (On Average MAR) model, we assume that all IMORs are equal, that is, <inline-formula id="inline-formula52-1740774512470317">
<mml:math display="inline" id="math60-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>all</mml:mi>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math></inline-formula> and place a prior distribution <inline-formula id="inline-formula53-1740774512470317">
<mml:math display="inline" id="math61-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>all</mml:mi>
</mml:mrow>
</mml:msup>
</mml:mrow>
<mml:mrow>
<mml:mspace width="0.25em"/>
</mml:mrow>
</mml:msub>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:mo>,</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> on the parameter with <inline-formula id="inline-formula54-1740774512470317">
<mml:math display="inline" id="math62-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math></inline-formula> and <inline-formula id="inline-formula55-1740774512470317">
<mml:math display="inline" id="math63-1740774512470317">
<mml:mrow>
<mml:mi>σ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>5</mml:mn>
</mml:mrow>
</mml:math></inline-formula>. This model expresses considerable uncertainty in whether MAR holds; the odds of a success being missing ranges from 166% higher to 62% lower than the odds of a failure being missing. The common IMOR model allows us to estimate a single parameter <inline-formula id="inline-formula56-1740774512470317">
<mml:math display="inline" id="math64-1740774512470317">
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>all</mml:mi>
</mml:mrow>
</mml:msup>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> that measures the departure from MAR.</p>
<p>The fact that information about different treatments is available allows us to investigate the association between specific treatments and missingness. For example, it is possible that participants randomized at an active treatment are MAR, whereas participant randomized to placebo or to an ineffective treatment dropout because of lack of efficacy. In the treatment-specific IMOR model, we assume <inline-formula id="inline-formula57-1740774512470317">
<mml:math display="inline" id="math65-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula>, where <inline-formula id="inline-formula58-1740774512470317">
<mml:math display="inline" id="math66-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> is the treatment in the arm <inline-formula id="inline-formula59-1740774512470317">
<mml:math display="inline" id="math67-1740774512470317">
<mml:mrow>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:math></inline-formula> in study <inline-formula id="inline-formula60-1740774512470317">
<mml:math display="inline" id="math68-1740774512470317">
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:math></inline-formula>. The model has as many log IMORs as treatments and we give them a common prior distribution</p>
<p>
<disp-formula id="disp-formula9-1740774512470317">
<mml:math display="block" id="math69-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msub>
<mml:mo>~</mml:mo>
<mml:mi>N</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mi>Δ</mml:mi>
<mml:mo>,</mml:mo>
<mml:msup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
<mml:mo>)</mml:mo>
</mml:mrow>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula9-1740774512470317" xlink:href="10.1177_1740774512470317-eq9.tif"/>
</disp-formula>
</p>
<p>The assumptions about missingness are again reflected in <inline-formula id="inline-formula61-1740774512470317">
<mml:math display="inline" id="math70-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
</mml:mrow>
</mml:math></inline-formula>, and the confidence in the assumptions is controlled by <inline-formula id="inline-formula62-1740774512470317">
<mml:math display="inline" id="math71-1740774512470317">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>σ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mn>2</mml:mn>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math></inline-formula>. Setting again <inline-formula id="inline-formula63-1740774512470317">
<mml:math display="inline" id="math72-1740774512470317">
<mml:mrow>
<mml:mi>σ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>5</mml:mn>
</mml:mrow>
</mml:math></inline-formula>, we achieve a rather large uncertainty in the imputations. We explored the impact in the relative treatment estimates under several assumptions:</p>
<list id="list3-1740774512470317" list-type="order">
<list-item>
<p>Successes are as likely to be missing as failures (On Average MAR) with <inline-formula id="inline-formula64-1740774512470317">
<mml:math display="inline" id="math73-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math></inline-formula>;</p>
</list-item>
<list-item>
<p>Failures are more likely to be missing rather than successes (more missing failures (MMF)) when <inline-formula id="inline-formula65-1740774512470317">
<mml:math display="inline" id="math74-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>log</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">/</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> for <inline-formula id="inline-formula66-1740774512470317">
<mml:math display="inline" id="math75-1740774512470317">
<mml:mrow>
<mml:mi>λ</mml:mi>
<mml:mo>&gt;</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:math></inline-formula>;</p>
</list-item>
<list-item>
<p>Successes are more likely to be missing rather than failures (more missing successes (MMS)) when <inline-formula id="inline-formula67-1740774512470317">
<mml:math display="inline" id="math76-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>log</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> for <inline-formula id="inline-formula68-1740774512470317">
<mml:math display="inline" id="math77-1740774512470317">
<mml:mrow>
<mml:mi>λ</mml:mi>
<mml:mo>&gt;</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:math></inline-formula>;</p>
</list-item>
<list-item>
<p>Most of the missing patients in placebo arm have failed, while most of the missing patients in the active treatments have succeeded (more failures in placebo (MFP)) when <inline-formula id="inline-formula69-1740774512470317">
<mml:math display="inline" id="math78-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>log</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> for the active treatments and <inline-formula id="inline-formula70-1740774512470317">
<mml:math display="inline" id="math79-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>log</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">/</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> for the placebo arm for <inline-formula id="inline-formula71-1740774512470317">
<mml:math display="inline" id="math80-1740774512470317">
<mml:mrow>
<mml:mi>λ</mml:mi>
<mml:mo>&gt;</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:math></inline-formula>;</p>
</list-item>
<list-item>
<p>Most of the missing patients in placebo arm have succeeded, while most of the missing patients in the active treatments have failed (more successes in placebo (MSP)) with <inline-formula id="inline-formula72-1740774512470317">
<mml:math display="inline" id="math81-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>log</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">/</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> for the active treatments and <inline-formula id="inline-formula73-1740774512470317">
<mml:math display="inline" id="math82-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>log</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>λ</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> for the placebo arm for <inline-formula id="inline-formula74-1740774512470317">
<mml:math display="inline" id="math83-1740774512470317">
<mml:mrow>
<mml:mi>λ</mml:mi>
<mml:mo>&gt;</mml:mo>
<mml:mn>1</mml:mn>
</mml:mrow>
</mml:math></inline-formula>.</p>
</list-item>
</list>
<p>The parameter <inline-formula id="inline-formula75-1740774512470317">
<mml:math display="inline" id="math84-1740774512470317">
<mml:mrow>
<mml:mi>λ</mml:mi>
</mml:mrow>
</mml:math></inline-formula> is to be specified based on clinical judgment. For this application, we used <italic>λ</italic> = 2, suggesting that the odds of missing a success are half the odds of missing a failure under the MMF model.</p>
</sec>
<sec id="section15-1740774512470317">
<title>Model estimation</title>
<p>The WinBUGS software was used to fit all models [<xref ref-type="bibr" rid="bibr18-1740774512470317">18</xref>]. The analyses used 100,000 updates and a burn-in of the 10,000 primary samples. For the parameters <inline-formula id="inline-formula76-1740774512470317">
<mml:math display="inline" id="math85-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>u</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> and <inline-formula id="inline-formula77-1740774512470317">
<mml:math display="inline" id="math86-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>μ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>R</mml:mi>
<mml:mtext>X</mml:mtext>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula>, we used non-informative normal prior distributions centred at zero with variance equal to 10,000. For <inline-formula id="inline-formula78-1740774512470317">
<mml:math display="inline" id="math87-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>γ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> and <inline-formula id="inline-formula79-1740774512470317">
<mml:math display="inline" id="math88-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula>, we used normal distribution <inline-formula id="inline-formula80-1740774512470317">
<mml:math display="inline" id="math89-1740774512470317">
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>1000</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> and <inline-formula id="inline-formula81-1740774512470317">
<mml:math display="inline" id="math90-1740774512470317">
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>.</mml:mo>
<mml:mn>25</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>, respectively. For heterogeneity standard deviation, we used half normal distribution <inline-formula id="inline-formula82-1740774512470317">
<mml:math display="inline" id="math91-1740774512470317">
<mml:mrow>
<mml:mi>N</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>I</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>0</mml:mn>
<mml:mo>,</mml:mo>
<mml:mi>∞</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula>. In order to reduce autocorrelation, we used thinning to every 40th value. The WinBUGS code is available online at <ext-link ext-link-type="uri" xlink:href="http://www.mtm.uoi.gr">www.mtm.uoi.gr</ext-link> under ‘Material from Publications’.</p>
</sec>
</sec>
<sec id="section16-1740774512470317" sec-type="results">
<title>Results</title>
<p>
<xref ref-type="table" rid="table1-1740774512470317">Tables 1</xref> and <xref ref-type="table" rid="table2-1740774512470317">2</xref> present the treatments, number of studies, randomized sample size, and proportion missing for the network of anti-manic and antidepressant treatments, respectively. The missing rate ranged from 0% to 7% for the anti-manic network and from 2% to 12% for the antidepressant network. <xref ref-type="fig" rid="fig1-1740774512470317">Figures 1</xref> and <xref ref-type="fig" rid="fig2-1740774512470317">2</xref> present the relative effectiveness (in OR) of each anti-manic treatment versus placebo and each antidepressant versus fluoxetine under the different models for missing outcome data. The relative effectiveness of anti-manic drugs is affected only by the two extreme scenarios of WC and BC where their relative effectiveness drops and increases, respectively. <xref ref-type="fig" rid="fig3-1740774512470317">Figure 3</xref> shows how the heterogeneity changes under the various missing data scenarios. Large heterogeneity values suggest increased variability between study effects and provide evidence against the employed scenario.</p>
<table-wrap id="table1-1740774512470317" position="float">
<label>Table 1.</label>
<caption><p>Total number of trials, randomized patients and percentages of missing summarized for anti-manic treatment arms and placebo</p></caption>
<graphic alternate-form-of="table1-1740774512470317" xlink:href="10.1177_1740774512470317-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Treatments</th>
<th align="left">Total number of trials</th>
<th align="left" colspan="2">Total number of patients<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="left">Missing (%)</th>
<th align="left">Randomized</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aripiprazole</td>
<td>7</td>
<td>2</td>
<td>1284</td>
</tr>
<tr>
<td>Placebo</td>
<td>36</td>
<td>5</td>
<td>4102</td>
</tr>
<tr>
<td>Lithium</td>
<td>8</td>
<td>1</td>
<td>490</td>
</tr>
<tr>
<td>Haloperidol</td>
<td>8</td>
<td>3</td>
<td>1000</td>
</tr>
<tr>
<td>Quetiapine</td>
<td>7</td>
<td>3</td>
<td>832</td>
</tr>
<tr>
<td>Ziprasidone</td>
<td>5</td>
<td>5</td>
<td>1018</td>
</tr>
<tr>
<td>Olanzapine</td>
<td>13</td>
<td>7</td>
<td>1636</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>1</td>
<td>0</td>
<td>15</td>
</tr>
<tr>
<td>Divalproex</td>
<td>8</td>
<td>4</td>
<td>706</td>
</tr>
<tr>
<td>Risperidoneand paliperidone</td>
<td>7</td>
<td>7</td>
<td>1215</td>
</tr>
<tr>
<td>Asenapine</td>
<td>1</td>
<td>3</td>
<td>194</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>3</td>
<td>4</td>
<td>246</td>
</tr>
<tr>
<td>Topiramate</td>
<td>1</td>
<td>5</td>
<td>143</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table2-1740774512470317" position="float">
<label>Table 2.</label>
<caption>
<p>Total number of trials, randomized patients and percentages of missing summarized for antidepressant treatment arms</p>
</caption>
<graphic alternate-form-of="table2-1740774512470317" xlink:href="10.1177_1740774512470317-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Treatments</th>
<th align="left">Total number of trials</th>
<th align="left" colspan="2">Total number of patients<hr/></th>
</tr>
<tr>
<th/>
<th/>
<th align="left">Missing (%)</th>
<th align="left">Randomized</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paroxetine</td>
<td>28</td>
<td>4</td>
<td>2989</td>
</tr>
<tr>
<td>Sertraline</td>
<td>25</td>
<td>5</td>
<td>5171</td>
</tr>
<tr>
<td>Citalopram</td>
<td>14</td>
<td>4</td>
<td>779</td>
</tr>
<tr>
<td>Escitalopram</td>
<td>16</td>
<td>2</td>
<td>569</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>53</td>
<td>6</td>
<td>2910</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>11</td>
<td>12</td>
<td>689</td>
</tr>
<tr>
<td>Milnacipran</td>
<td>6</td>
<td>4</td>
<td>1623</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>27</td>
<td>3</td>
<td>1299</td>
</tr>
<tr>
<td>Reboxetine</td>
<td>8</td>
<td>3</td>
<td>1368</td>
</tr>
<tr>
<td>Bupropion</td>
<td>12</td>
<td>3</td>
<td>2289</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>12</td>
<td>5</td>
<td>1939</td>
</tr>
<tr>
<td>Duloxetine</td>
<td>8</td>
<td>3</td>
<td>2504</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="fig1-1740774512470317" position="float">
<label>Figure 1.</label>
<caption>
<p>ORs for efficacy of anti-manic treatments against placebo with 95% posterior intervals for fixed IMOR (MAR, AMF, AMS, BC, and WC), common IMOR (On Average MAR), treatment-specific IMOR (On Average MAR), and variations of the treatment-specific IMOR model (MMF, MMS, MFP, and MSP).</p>
<p>OR: odds ratio; IMOR: informative missing odds ratio; MAR: missing at random; AMF: all missing failures; AMS: all missing successes; BC: best case; WC: worst case; Com(MAR): common informative missing odds ratio (on average missing at random); Treat(MAR): treatment-specific informative missing odds ratio (on average missing at random); Treat(MMF): treatment-specific informative missing odds ratio (more missing failures); Treat(MMS): treatment-specific informative missing odds ratio (more missing successes); Treat(MFP): treatment-specific informative missing odds ratio (more failures in placebo); Treat(MSP): treatment-specific informative missing odds ratio (more successes in placebo).</p>
</caption>
<graphic xlink:href="10.1177_1740774512470317-fig1.tif"/>
</fig>
<fig id="fig2-1740774512470317" position="float">
<label>Figure 2.</label>
<caption>
<p>ORs for efficacy of antidepressant treatments against fluoxetine with 95% posterior intervals for fixed IMOR models (MAR, AMF, AMS, BC, and WC), common IMOR (On Average MAR), treatment-specific IMOR (On Average MAR), and variations of the treatment-specific IMOR.</p>
<p>OR: odds ratio; IMOR: informative missing odds ratio; MAR: missing at random; AMF: all missing failures; AMS: all missing successes; BC: best case; WC: worst case; Com(MAR): common informative missing odds ratio (on average missing at random); Treat(MAR): treatment-specific informative missing odds ratio (on average missing at random); Treat(MMF): treatment-specific informative missing odds ratio (more missing failures); Treat(MMS): treatment-specific informative missing odds ratio (more missing successes); Treat(MFF): treatment-specific informative missing odds ratio (more failures in fluoxetine); Treat(MSF): treatment-specific informative missing odds ratio (more successes in fluoxetine).</p>
</caption>
<graphic xlink:href="10.1177_1740774512470317-fig2.tif"/>
</fig>
<fig id="fig3-1740774512470317" position="float">
<label>Figure 3.</label>
<caption>
<p>Common heterogeneity standard deviation (<inline-formula id="inline-formula83-1740774512470317">
<mml:math display="inline" id="math92-1740774512470317">
<mml:mrow>
<mml:mi>τ</mml:mi>
</mml:mrow>
</mml:math></inline-formula>) of log OR with 95% posterior intervals for fixed IMOR models (MAR, AMF, AMS, BC, and WC), common IMOR (On Average MAR), treatment-specific IMOR (On Average MAR), and variations of the treatment-specific IMOR model (MMF, MMS, MFP, MSP, MFF, and MSF) in anti-manic and antidepressant networks.</p>
<p>IMOR: informative missing odds ratio; MAR: missing at random; AMF: all missing failures; AMS: all missing successes; BC: best case; WC: worst case; Com (MAR): common informative missing odds ratio (on average missing at random); Treat(MAR): treatment-specific informative missing odds ratio (on average missing at random); Treat(MMF): treatment-specific informative missing odds ratio (more missing failures); Treat(MMS): treatment-specific informative missing odds ratio (more missing successes); Treat(MFP): treatment-specific informative missing odds ratio (more failures in placebo); Treat(MSP): treatment-specific informative missing odds ratio (more successes in placebo); Treat(MFF): treatment-specific informative missing odds ratio (more failures in fluoxetine); Treat(MSF): treatment-specific informative missing odds ratio (more successes in fluoxetine).</p>
</caption>
<graphic xlink:href="10.1177_1740774512470317-fig3.tif"/>
</fig>
<p>In both datasets, the heterogeneity increases for WC and BC scenarios indicating that these assumptions might be too extreme to make across all studies. Under the BC and WC scenarios, heterogeneity increases from 0.29 in MAR to 0.35 and 0.45, respectively, in anti-manic trials and from 0.08 in MAR to 0.22 and 0.17, respectively, in antidepressant trials. Overall, the original analysis (the AMF scenario) seems to be robust to uncertainty in the imputations. Consequently, there is little impact on the mean SUCRA values of the treatments and results into small change in their ranking within each network (Tables A1 and A2 in Appendix). For instance, the anti-manic treatment lithium ranks fifth under MAR and AMS models but seventh under AMF model, and the antidepressant treatment mirtazapine ranks second under MAR model but first and third under the AMF and AMS models, respectively.</p>
<p>
<xref ref-type="fig" rid="fig4-1740774512470317">Figure 4</xref> shows the estimated means and 95% intervals for log IMORs <inline-formula id="inline-formula84-1740774512470317">
<mml:math display="inline" id="math93-1740774512470317">
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:msub>
<mml:mrow>
<mml:mi>t</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>i</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>k</mml:mi>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:msub>
</mml:mrow>
</mml:math></inline-formula> and <inline-formula id="inline-formula85-1740774512470317">
<mml:math display="inline" id="math94-1740774512470317">
<mml:mrow>
<mml:msup>
<mml:mrow>
<mml:mi>δ</mml:mi>
</mml:mrow>
<mml:mrow>
<mml:mi>all</mml:mi>
</mml:mrow>
</mml:msup>
</mml:mrow>
</mml:math></inline-formula>. Mean values away from zero suggest departure from the MAR assumption. The prior information about log IMORs is represented by the interval between the two vertical lines. As most posteriors intervals overlap with the prior, we conclude that the data provide little information about the informativeness of missing outcomes, and there is no evidence for or against the MAR assumption. In the network of anti-manic drugs, there is a weak indication that successes in placebo have lower odds to be missing compared with failures (<xref ref-type="fig" rid="fig4-1740774512470317">Figure 4(a)</xref>) because its posterior interval is moved slightly towards the negative values. The same might be true for paroxetine in the antidepressants network (<xref ref-type="fig" rid="fig4-1740774512470317">Figure 4(b)</xref>). Lack of efficacy in placebo and paroxetine may be the reason that patients fail to respond to these treatments and tend to be missing. In contrast, successes in sertraline, fluoxetine, and fluvoxamine have higher odds to be missing than failures because the corresponding posterior intervals are slightly moved towards the positive values and protrude a little from the upper bound of the prior interval.</p>
<fig id="fig4-1740774512470317" position="float">
<label>Figure 4.</label>
<caption>
<p>Log IMORs with 95% posterior intervals for treatment-specific (On Average MAR) and common (On Average MAR) IMOR models in anti-manic and antidepressant networks. The black vertical lines are the boundaries of the 95% prior interval.</p>
<p>IMOR: informative missing odds ratio; MAR: missing at random; Com(MAR): common informative missing odds ratio (on average missing at random).</p>
</caption>
<graphic xlink:href="10.1177_1740774512470317-fig4.tif"/>
</fig>
<p>As an ad hoc sensitivity analysis driven by the posterior values of log IMORs, we re-analysed the antidepressants network assuming <inline-formula id="inline-formula86-1740774512470317">
<mml:math display="inline" id="math95-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>log</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo stretchy="false">/</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> for paroxetine, <inline-formula id="inline-formula87-1740774512470317">
<mml:math display="inline" id="math96-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mi>log</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>2</mml:mn>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:math></inline-formula> for sertraline, fluoxetine, and fluvoxamine and <inline-formula id="inline-formula88-1740774512470317">
<mml:math display="inline" id="math97-1740774512470317">
<mml:mrow>
<mml:mi>Δ</mml:mi>
<mml:mo>=</mml:mo>
<mml:mn>0</mml:mn>
</mml:mrow>
</mml:math></inline-formula> for all other treatments. <xref ref-type="fig" rid="fig5-1740774512470317">Figure 5</xref> presents the cumulative ranking curves from the ad hoc sensitivity analysis along with the curves from the initial analysis (AMF). The SUCRA values and the ranking change for most treatments.</p>
<fig id="fig5-1740774512470317" position="float">
<label>Figure 5.</label>
<caption>
<p>Cumulative ranking probability plots for the antidepressant treatments. The AMF analysis is illustrated with solid lines and the ad hoc sensitivity analysis with dashed lines. The ranks are on the horizontal axis, and the cumulative probability of each treatment being the best option, among the best two options, among the best three options, and so on, is on the vertical axis. The surface under the cumulative ranking curve of each treatment represents the overall ranking of treatments.</p>
<p>AMF: all missing failures.</p>
</caption>
<graphic xlink:href="10.1177_1740774512470317-fig5.tif"/>
</fig>
</sec>
<sec id="section17-1740774512470317" sec-type="discussion">
<title>Discussion</title>
<p>We have extended the conventional meta-analysis model to a NMA model that quantifies the relative effectiveness of multiple interventions and enables ranking of all treatments in the presence of attrition and reflects the uncertainty about imputing unobserved outcomes. Sensitivity analysis via assumptions about the IMOR parameter can contribute to the reliability of the inferences from meta-analysis and about the impact of attrition in meta-analysis. We have evaluated the performance of this model on two published meta-analyses that compared antidepressants [<xref ref-type="bibr" rid="bibr16-1740774512470317">16</xref>] and anti-manic drugs [<xref ref-type="bibr" rid="bibr15-1740774512470317">15</xref>]. In these examples involving 325 studies in total, the impact of missing outcome data was small and the relative effectiveness of the treatments was not affected by the different scenarios. There was only a small change in the ranking of most of the treatments. These can be partly explained by the low missing outcome data rate.</p>
<p>We suggest that protocols for meta-analyses include a pre-specified strategy to address and present results specific to the various missing data analyses. Significant changes in the relative effectiveness and ranking of treatments should be expected when the amount of and reasons for missing data differ across arms. In this case, it is important that the results from the various missing data scenarios are presented in a transparent way. Clinical understanding should determine which of the scenarios is most plausible and should be used as a primary analysis. Results from other scenarios can then be presented as part of a sensitivity analysis and can be compared by superimposing cumulative ranking probability plots. Although SUCRAs provide useful information about the ranking of competing treatments, they cannot indicate whether differences between interventions are clinically important. Therefore, they should always be presented alongside the effect measures and their uncertainty.</p>
<p>In our model framework, we have the flexibility to employ different assumptions about the distribution of IMORs; assumptions regarding how informative is missingness across trials and arms and investigate their impact on the relative effectiveness of the compared treatments. We examined in detail the use of treatment-specific IMOR models because they allow the degree of informative missingness to be different across the treatments. For example, it may be reasonable to assume that participants in aripiprazole leave the study due to adverse events despite its efficacy (and therefore consider a prior IMOR more than 1), whereas placebo participants leave the study due to lack of efficacy (and hence employ a prior IMOR less than 1). Both anti-manic and antidepressant treatments provided little information regarding the informative missingness of the outcomes, again possibly due to low missing outcome rate.</p>
<p>Missing outcomes are commonplace in psychiatric populations. Two factors are likely to have led to the low missing outcome rates in our datasets. First, the application of intention-to-treat (ITT) analysis (e.g., using LOCF) means that most participants with at least one post-randomization observation were included in the dataset (as non-missing). Since the late 1980s, the ITT approach has been widely endorsed in the regulatory guidelines as the preferred analysis strategy. True ITT preserves the benefits of randomization, preventing the effects of premature discontinuation and illustrating the efficacy of the allocated treatments regardless of the participants’ compliance. Nevertheless, the use of LOCF specifically has been discouraged in more recent guidelines [<xref ref-type="bibr" rid="bibr19-1740774512470317">19</xref><xref ref-type="bibr" rid="bibr20-1740774512470317"/>–<xref ref-type="bibr" rid="bibr21-1740774512470317">21</xref>]. Second, the majority of antidepressant studies had a placebo run-in phase. After screening of participants, the run-in phase is the period of time that is used to select or exclude patients in a clinical trial before randomization. Even though they may increase internal validity and suggest a trial sample of patients with high compliance rate, run-ins may affect generalizability and the overall applicability of findings [<xref ref-type="bibr" rid="bibr22-1740774512470317">22</xref>].</p>
<p>Detecting the missing data mechanism is challenging and we often rely on assumptions. From the meta-analysis perspective where only some published information is available, researchers need to analyse the data based on untestable assumptions. Developing sensible assumptions requires clinical insight and some clinical research topics are more prone to informative missingness than others. Large differences in the reasons for missingness may exist between treatments, and the risk of bias because of incomplete outcome data may be high [<xref ref-type="bibr" rid="bibr3-1740774512470317">3</xref>]. Meta-analyses should not ignore the risk of meta-confounding between the amount of missing outcome data in trials and the corresponding estimated treatment effect [<xref ref-type="bibr" rid="bibr6-1740774512470317">6</xref>].</p>
<p>There are several limitations in the application of the findings from the present article. First, we investigated the differences in attrition only between treatments. Employing further models to study whether the degree of informative missingness differs between studies and arms (trial-specific and arm-specific IMOR models) could supplement the information provided by the treatment-specific IMOR models. Second, meta-analysis for missing participants’ outcome data has been implemented using prior beliefs about the informative missingness, reflected in different prior assumptions to represent our expectations about the missing outcome data. Non-informative priors could be implemented but are unlikely to be useful because there is very little information in the data about the IMOR parameters. Third, we have not applied any sensitivity analysis in the selection of IMOR priors and particularly the choice of the prior distributions for heterogeneity of the IMORs. Different specifications of prior distributions could affect the results. Sensitivity analysis to measure the robustness of the results regarding the selection of prior distributions of the IMORs should always be carried out. The robustness of the final results in terms of posterior distributions in meta-analysis would depend on whether the results obtained have been unchanged via a sensitivity analysis [<xref ref-type="bibr" rid="bibr23-1740774512470317">23</xref>]. Fourth, the IMOR approach described extends the meta-analysis model for dichotomous outcome measures only. Extensions of the models to continuous and repeated outcome measures need to be developed.</p>
<p>The most important limitation of the model presented is that it addresses only part of the missing data problem in psychiatric trials. The missing outcome rate was very low in all treatments in our examples because the LOCF imputed outcomes were treated as fully observed. Treating LOCF imputed outcomes as missing data was impossible in our examples as investigators rarely reported numbers of successes and failures for completers alone. Further extension of the IMOR model to account for the uncertainty in the imputed outcomes is needed to study fully the robustness of the meta-analysis findings.</p>
<p>In conclusion, models that quantify departures from MAR in order to handle attrition in RCTs are available and can be applied not only in a simple meta-analysis but also in a NMA situation. In the field of psychiatry, where dropout rates are high and missing is informative, it is important to investigate the extent to which informative missing outcome data may have distorted the conclusions of RCTs and meta-analyses. An appealing attribute of IMOR approach is that it allows the investigation of all possible scenarios for the outcome of the missing participants while taking into account the uncertainty of each scenario. From a clinical and meta-analysis perspective, it is desirable to use plausible prior distributions about these scenarios, elicited from subject matter experts.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research was financially supported by the European Research Council (to G.S. and L.M.S.) (grant agreement number 260559 IMMA) and Medical Research Council (to J.P.T.H.) (Unit Programme number U105285807).</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1740774512470317">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tierney</surname><given-names>FJ</given-names></name>
<name><surname>Stewart</surname><given-names>AL</given-names></name>
</person-group>. <article-title>Investigating patient exclusion bias in meta-analysis</article-title>. <source>Int J Epidemiol</source> <year>2005</year>; <volume>34</volume>(<issue>1</issue>): <fpage>79</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr2-1740774512470317">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nuesch</surname><given-names>E</given-names></name>
<name><surname>Trelle</surname><given-names>S</given-names></name>
<name><surname>Reichenbach</surname><given-names>S</given-names></name>
<etal/>
</person-group>. <article-title>The effects of excluding patients from the analysis in randomised controlled trials: Meta-epidemiological study</article-title>. <source>BMJ</source> <year>2009</year>; <volume>339</volume>: <fpage>b3244</fpage>.</citation>
</ref>
<ref id="bibr3-1740774512470317">
<label>3.</label>
<citation citation-type="web">
<person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>PTJ</given-names></name>
<name><surname>Altman</surname><given-names>GD</given-names></name>
<name><surname>Sterne</surname><given-names>ACJ</given-names></name>
</person-group>. <article-title>Assessing risk of bias in included studies</article-title>. In <person-group person-group-type="editor">
<name><surname>Higgins</surname><given-names>PTJ</given-names></name>
<name><surname>Hollis</surname><given-names>S</given-names></name>
</person-group> (eds). <source>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</source>. <collab>The Cochrane Collaboration</collab>, <year>2011</year>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.cochrane-handbook.org">www.cochrane-handbook.org</ext-link></citation>
</ref>
<ref id="bibr4-1740774512470317">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>RI</given-names></name>
<name><surname>Higgins</surname><given-names>PTJ</given-names></name>
<name><surname>Wood</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Allowing for uncertainty due to missing data in meta-analysis – Part 1: Two-stage methods</article-title>. <source>Stat Med</source> <year>2008</year>; <volume>27</volume>(<issue>5</issue>): <fpage>711</fpage>–<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr5-1740774512470317">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>White</surname><given-names>RI</given-names></name>
<name><surname>Welton</surname><given-names>JN</given-names></name>
<name><surname>Wood</surname><given-names>MA</given-names></name>
<etal/>
</person-group>. <article-title>Allowing for uncertainty due to missing data in meta-analysis – Part 2: Hierarchical models</article-title>. <source>Stat Med</source> <year>2008</year>; <volume>27</volume>(<issue>5</issue>): <fpage>728</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr6-1740774512470317">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Higgins</surname><given-names>PTJ</given-names></name>
<name><surname>White</surname><given-names>RI</given-names></name>
<name><surname>Wood</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Imputation methods for missing outcome data in meta-analysis of clinical trials</article-title>. <source>Clin Trials</source> <year>2008</year>; <volume>5</volume>(<issue>3</issue>): <fpage>225</fpage>–<lpage>39</lpage>.</citation>
</ref>
<ref id="bibr7-1740774512470317">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gamble</surname><given-names>C</given-names></name>
<name><surname>Hollis</surname><given-names>S</given-names></name>
</person-group>. <article-title>Uncertainty method improved on best–worst case analysis in a binary meta-analysis</article-title>. <source>J Clin Epidemiol</source> <year>2005</year>; <volume>58</volume>(<issue>6</issue>): <fpage>579</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr8-1740774512470317">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Magder</surname><given-names>SL</given-names></name>
</person-group>. <article-title>Simple approaches to assess the possible impact of missing outcome information on estimates of risk ratios, odds ratios, and risk differences</article-title>. <source>Control Clin Trials</source> <year>2003</year>; <volume>24</volume>(<issue>4</issue>): <fpage>411</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr9-1740774512470317">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hollis</surname><given-names>S</given-names></name>
</person-group>. <article-title>A graphical sensitivity analysis for clinical trials with non-ignorable missing binary outcome</article-title>. <source>Stat Med</source> <year>2002</year>; <volume>21</volume>(<issue>24</issue>): <fpage>3823</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr10-1740774512470317">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leon</surname><given-names>CA</given-names></name>
<name><surname>Mallinckrodt</surname><given-names>HC</given-names></name>
<name><surname>Chuang-Stein</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Attrition in randomized controlled clinical trials: Methodological issues in psychopharmacology</article-title>. <source>Biol Psychiatry</source> <year>2006</year>; <volume>59</volume>(<issue>11</issue>): <fpage>1001</fpage>–<lpage>05</lpage>.</citation>
</ref>
<ref id="bibr11-1740774512470317">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Leucht</surname><given-names>S</given-names></name>
<name><surname>Engel</surname><given-names>RR</given-names></name>
<name><surname>Bauml</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Is the superior efficacy of new generation antipsychotics an artifact of LOCF?</article-title> <source>Schizophrenia Bull</source> <year>2007</year>; <volume>33</volume>(<issue>1</issue>): <fpage>183</fpage>–<lpage>91</lpage>.</citation>
</ref>
<ref id="bibr12-1740774512470317">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mallinckrodt</surname><given-names>HC</given-names></name>
<name><surname>Watkin</surname><given-names>GJ</given-names></name>
<name><surname>Molenberghs</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Choice of the primary analysis in longitudinal clinical trials</article-title>. <source>Pharm Stat</source> <year>2004</year>; <volume>3</volume>(<issue>3</issue>): <fpage>161</fpage>–<lpage>69</lpage>.</citation>
</ref>
<ref id="bibr13-1740774512470317">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salanti</surname><given-names>G</given-names></name>
<name><surname>Ades</surname><given-names>EA</given-names></name>
<name><surname>Ioannidis</surname><given-names>PAJ</given-names></name>
</person-group>. <article-title>Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial</article-title>. <source>J Clin Epidemiol</source> <year>2010</year>; <volume>64</volume>(<issue>2</issue>): <fpage>163</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr14-1740774512470317">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Salanti</surname><given-names>G</given-names></name>
<name><surname>Higgins</surname><given-names>PTJ</given-names></name>
<name><surname>Ades</surname><given-names>EA</given-names></name>
<name><surname>Ioannidis</surname><given-names>PAJ</given-names></name>
</person-group>. <article-title>Evaluation of networks of randomized trials</article-title>. <source>Stat Methods Med Res</source> <year>2008</year>; <volume>17</volume>(<issue>3</issue>): <fpage>279</fpage>–<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr15-1740774512470317">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Barbui</surname><given-names>C</given-names></name>
<name><surname>Salanti</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Comparative efficacy and acceptability of antimanic drugs in acute mania: A multiple-treatments meta-analysis</article-title>. <source>Lancet</source> <year>2011</year>; <volume>378</volume>(<issue>9799</issue>): <fpage>1306</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr16-1740774512470317">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Furukawa</surname><given-names>T</given-names></name>
<name><surname>Salanti</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis</article-title>. <source>Lancet</source> <year>2009</year>; <volume>373</volume>(<issue>9665</issue>): <fpage>746</fpage>–<lpage>58</lpage>.</citation>
</ref>
<ref id="bibr17-1740774512470317">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lu</surname><given-names>G</given-names></name>
<name><surname>Ades</surname><given-names>AE</given-names></name>
</person-group>. <article-title>Combination of direct and indirect evidence in mixed treatment comparisons</article-title>. <source>Stat Med</source> <year>2004</year>; <volume>23</volume>(<issue>20</issue>): <fpage>3105</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr18-1740774512470317">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lunn</surname><given-names>DJ</given-names></name>
<name><surname>Thomas</surname><given-names>A</given-names></name>
<name><surname>Best</surname><given-names>N</given-names></name>
<etal/>
</person-group>. <article-title>WinBUGS – A Bayesian modelling framework: Concepts, structure, and extensibility</article-title>. <source>Stat Comput</source> <year>2000</year>; <volume>10</volume>(<issue>4</issue>): <fpage>325</fpage>–<lpage>37</lpage>.</citation>
</ref>
<ref id="bibr19-1740774512470317">
<label>19.</label>
<citation citation-type="book">
<collab>Panel on Handling Missing Data in Clinical Trials, National Research Council</collab>. ‘<article-title>Front Matter’</article-title>. <source>The Prevention and Treatment of Missing Data in Clinical Trials</source>. <publisher-name>The National Academies Press</publisher-name>, <publisher-loc>Washington, DC</publisher-loc>, <year>2010</year>.</citation>
</ref>
<ref id="bibr20-1740774512470317">
<label>20.</label>
<citation citation-type="confproc">
<article-title>International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Statistical principles for clinical trials, Step 5: Note for guidance on statistical principles for clinical trials</article-title>. In <conf-name>International Conference on Harmonization (ICH) Topic E9</conf-name>, <conf-date>5 February 1998</conf-date>, Published in the Federal Register, p. <fpage>23</fpage>.</citation>
</ref>
<ref id="bibr21-1740774512470317">
<label>21.</label>
<citation citation-type="other">
<person-group person-group-type="author">
<name><surname>Helfand</surname><given-names>M</given-names></name>
<name><surname>Berg</surname><given-names>A</given-names></name>
<name><surname>Flum</surname><given-names>D</given-names></name>
<name><surname>Gabriel</surname><given-names>S</given-names></name>
<name><surname>Normand</surname><given-names>SL</given-names></name>
</person-group>. <article-title>Draft Methodology Report: ‘Our questions, our decisions: Standards for patient-centered outcomes research’</article-title>. <comment>Public comment draft report of the Patient-Centered Outcomes Research Institute (PCORI) Methodology Committee presented on 23 July 2012, and revised thereafter, 2012</comment>.</citation>
</ref>
<ref id="bibr22-1740774512470317">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Geddes</surname><given-names>JR</given-names></name>
</person-group>. <article-title>What is a run-in phase?</article-title> <source>Epidemiol Psichiatr Soc</source> <year>2010</year>; <volume>19</volume>(<issue>1</issue>): <fpage>21</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr23-1740774512470317">
<label>23.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Junaidi Stojanovski</surname><given-names>E</given-names></name>
<name><surname>Nur</surname><given-names>D</given-names></name>
</person-group>. <article-title>Prior sensitivity analysis for a hierarchical model</article-title>. In <conf-name>Proceedings of the Fourth Annual ASEARC Conference, Paper 13, University of Western Sydney</conf-name>, <conf-loc>Paramatta, NSW, Australia</conf-loc>, <conf-date>17–18 February 2011</conf-date>.</citation>
</ref>
</ref-list>
</back>
</article>